Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 68 articles: HTML format Text format

Single Articles

January 2019
1. DELLA CORTE CM, Gay CM, Byers LA
   Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.
   Cancer. 2019 Jan 8. doi: 10.1002/cncr.31863.
   PubMed     Text format    
   
   
   
2. PRINTZ C
   Currently recommended lung cancer screening guidelines may be insufficient for high-risk minorities.
   Cancer. 2019;125:10-11.
   PubMed     Text format    
   
   
   December 2018
3. NAZHA B, Owonikoko TK
   The clinical conundrum of managing relapsed small cell lung cancer.
   Cancer. 2018 Dec 18. doi: 10.1002/cncr.31849.
   PubMed     Text format    
   
   
   
4. NG TL, Liu Y, Dimou A, Patil T, et al
   Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
   Cancer. 2018 Dec 11. doi: 10.1002/cncr.31871.
   PubMed     Text format     Abstract available
   
   
   
5. MCFARLAND DC, Shaffer K, Breitbart W, Rosenfeld B, et al
   C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.
   Cancer. 2018 Dec 6. doi: 10.1002/cncr.31859.
   PubMed     Text format     Abstract available
   
   
   
6. AHN MJ, Tsai CM, Shepherd FA, Bazhenova L, et al
   Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-Term follow-up from a pooled analysis of 2 phase 2 studies.
   Cancer. 2018 Dec 4. doi: 10.1002/cncr.31891.
   PubMed     Text format     Abstract available
   
   
   November 2018
7. MORGENSZTERN D, Cobo M, Ponce Aix S, Postmus PE, et al
   ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
   Cancer. 2018 Nov 1. doi: 10.1002/cncr.31779.
   PubMed     Text format     Abstract available
   
   
   
8. GOLDBERG SB, Herbst RS
   Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
   Cancer. 2018 Nov 1. doi: 10.1002/cncr.31681.
   PubMed     Text format    
   
   
   October 2018
9. STINCHCOMBE TE, Fan W, Schild SE, Vokes EE, et al
   A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
   Cancer. 2018 Oct 21. doi: 10.1002/cncr.31813.
   PubMed     Text format     Abstract available
   
   
   September 2018
10. HATA A, Katakami N, Kaji R, Yokoyama T, et al
    Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study).
    Cancer. 2018 Sep 7. doi: 10.1002/cncr.31678.
    PubMed     Text format     Abstract available
    
    
    
11. 
    Declining lung cancer death rates lag for women in 2 US hot spots.
    Cancer. 2018;124:3467.
    PubMed     Text format    
    
    
    August 2018
12. 
    Neoadjuvant Nivolumab Safe, Led to Major Response Rates in Resectable Lung Cancer.
    Cancer. 2018;124:3283.
    PubMed     Text format    
    
    
    June 2018
13. PATEL JD, Chmura SJ
    Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
    Cancer. 2018 Jun 15. doi: 10.1002/cncr.31557.
    PubMed     Text format    
    
    
    May 2018
14. GOLDWASSER F, Vinant P, Aubry R, Rochigneux P, et al
    Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.
    Cancer. 2018 May 9. doi: 10.1002/cncr.31536.
    PubMed     Text format     Abstract available
    
    
    April 2018
15. SPIGEL DR, Burris HA 3rd, Greco FA, Shih KC, et al
    Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31290.
    PubMed     Text format     Abstract available
    
    
    
16. ARBOUR KC, Riely GJ
    Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31289.
    PubMed     Text format    
    
    
    
17. PRINTZ C
    Lung cancer screening based on personal risk may save more lives.
    Cancer. 2018;124:1315.
    PubMed     Text format    
    
    
    March 2018
18. HIRSCH FR, Sequist LV, Gore I, Mooradian M, et al
    Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31313.
    PubMed     Text format     Abstract available
    
    
    February 2018
19. SPIGEL DR, Hainsworth JD, Joseph MJ, Shipley DL, et al
    Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.30986.
    PubMed     Text format     Abstract available
    
    
    January 2018
20. CASSIDY RJ, Zhang X, Switchenko JM, Patel PR, et al
    Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
    Cancer. 2018 Jan 8. doi: 10.1002/cncr.31077.
    PubMed     Text format     Abstract available
    
    
    December 2017
21. TANDBERG DJ, Tong BC, Ackerson BG, Kelsey CR, et al
    Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31196.
    PubMed     Text format     Abstract available
    
    
    
22. RICHARDS TB, Henley SJ, Puckett MC, Weir HK, et al
    Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5079-5099.
    PubMed     Text format     Abstract available
    
    
    
23. ASSI HI, Kamphorst AO, Moukalled NM, Ramalingam SS, et al
    Immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31105.
    PubMed     Text format     Abstract available
    
    
    
24. KATAKAMI N, Uchino J, Yokoyama T, Naito T, et al
    Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
    Cancer. 2017 Dec 4. doi: 10.1002/cncr.31128.
    PubMed     Text format     Abstract available
    
    
    
25. NIXON NA, Khan OF, Imam H, Tang PA, et al
    Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
    Cancer. 2017;123:4672-4679.
    PubMed     Text format     Abstract available
    
    
    
26. MANSOUR MSI, Seidal T, Mager U, Baigi A, et al
    Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Cancer. 2017;125:908-917.
    PubMed     Text format     Abstract available
    
    
    November 2017
27. HAHN EJ, Rayens MK, Wiggins AT, Gan W, et al
    Lung cancer incidence and the strength of municipal smoke-free ordinances.
    Cancer. 2017 Nov 28. doi: 10.1002/cncr.31142.
    PubMed     Text format     Abstract available
    
    
    
28. SPIEGEL ML, Goldman JW, Wolf BR, Nameth DJ, et al
    Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.
    Cancer. 2017 Nov 10. doi: 10.1002/cncr.31056.
    PubMed     Text format     Abstract available
    
    
    October 2017
29. STOY SP, Rosen L, Mueller J, Murgu S, et al
    Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.
    Cancer. 2017 Oct 20. doi: 10.1002/cncy.21941.
    PubMed     Text format     Abstract available
    
    
    
30. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available
    
    
    
31. HEYMANN JJ, Bulman WA, Swinarski D, Pagan CA, et al
    Programmed death-ligand 1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Cancer. 2017 Oct 12. doi: 10.1002/cncy.21937.
    PubMed     Text format     Abstract available
    
    
    
32. SULLIVAN DR, Ganzini L, Lapidus JA, Hansen L, et al
    Improvements in hospice utilization among patients with advanced-stage lung cancer in an integrated health care system.
    Cancer. 2017 Oct 10. doi: 10.1002/cncr.31047.
    PubMed     Text format     Abstract available
    
    
    
33. CASSIDY RJ, Zhang X, Patel PR, Shelton JW, et al
    Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cancer. 2017;123:3681-3690.
    PubMed     Text format     Abstract available
    
    
    September 2017
34. PILLAI RN, Behera M, Owonikoko TK, Kamphorst AO, et al
    Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31043.
    PubMed     Text format     Abstract available
    
    
    
35. ARBOUR KC, Kris MG, Riely GJ, Ni A, et al
    Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30990.
    PubMed     Text format     Abstract available
    
    
    
36. YANG D, Zhang X, Powell CA, Ni J, et al
    Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study.
    Cancer. 2017 Sep 20. doi: 10.1002/cncr.31020.
    PubMed     Text format     Abstract available
    
    
    
37. LAMBROS L, Guibourg B, Uguen A
    Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France.
    Cancer. 2017 Sep 11. doi: 10.1002/cncy.21919.
    PubMed     Text format    
    
    
    
38. TRONCONE G
    Reply to Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France.
    Cancer. 2017 Sep 11. doi: 10.1002/cncy.21918.
    PubMed     Text format    
    
    
    
39. PRINTZ C
    Nivolumab improves survival for patients with advanced lung cancer.
    Cancer. 2017;123:3211.
    PubMed     Text format    
    
    
    
40. SADETZKI S, Chetrit A, Freedman LS, Hakak N, et al
    Cancer risk among Holocaust survivors in Israel-A nationwide study.
    Cancer. 2017;123:3335-3345.
    PubMed     Text format     Abstract available
    
    
    August 2017
41. MOORE KN, Borghaei H, O'Malley DM, Jeong W, et al
    Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors.
    Cancer. 2017;123:3080-3087.
    PubMed     Text format     Abstract available
    
    
    
42. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available
    
    
    
43. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available
    
    
    
44. HUNG YP, Lovitch SB, Qian X
    Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.
    Cancer. 2017;125:604-614.
    PubMed     Text format     Abstract available
    
    
    
45. CAPPELLESSO R, Galasso M, Nicole L, Dabrilli P, et al
    miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cancer. 2017;125:635-643.
    PubMed     Text format     Abstract available
    
    
    July 2017
46. PISAPIA P, Lozano MD, Vigliar E, Bellevicine C, et al
    ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Cancer. 2017 Jul 25. doi: 10.1002/cncy.21899.
    PubMed     Text format     Abstract available
    
    
    
47. PILLAI RN, Behera M, Berry LD, Rossi MR, et al
    HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30869.
    PubMed     Text format     Abstract available
    
    
    
48. RWIGEMA JM, Verma V, Lin L, Berman AT, et al
    Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30870.
    PubMed     Text format     Abstract available
    
    
    June 2017
49. GOLDSTEIN DA, Bilal U, Prasad V
    Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30868.
    PubMed     Text format    
    
    
    
50. GAINOR JF
    Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
    Cancer. 2017 Jun 16. doi: 10.1002/cncy.21882.
    PubMed     Text format    
    
    
    
51. PRINTZ C
    Lung cancer screening rates remain very low among current and former smokers.
    Cancer. 2017;123:2189.
    PubMed     Text format    
    
    
    
52. LILO MT, Allison DB, Younes BK, Cui M, et al
    The critical role of EBUS-TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings.
    Cancer. 2017 Jun 13. doi: 10.1002/cncy.21886.
    PubMed     Text format     Abstract available
    
    
    
53. ZAKOWSKI MF
    Analytic inquiry: Molecular testing in lung cancer.
    Cancer. 2017;125.
    PubMed     Text format     Abstract available
    
    
    
54. BAUM JE, Zhang P, Hoda RS, Geraghty B, et al
    Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Cancer. 2017;125:398-406.
    PubMed     Text format     Abstract available
    
    
    May 2017
55. MINO-KENUDSON M
    Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.
    Cancer. 2017 May 4. doi: 10.1002/cncy.21873.
    PubMed     Text format    
    
    
    
56. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    PubMed     Text format     Abstract available
    
    
    
57. CHUANG JC, Neal JW
    The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30718.
    PubMed     Text format    
    
    
    April 2017
58. ERSEK M, Miller SC, Wagner TH, Thorpe JM, et al
    Association between aggressive care and bereaved families' evaluation of end-of-life care for veterans with non-small cell lung cancer who died in Veterans Affairs facilities.
    Cancer. 2017 Apr 17. doi: 10.1002/cncr.30700.
    PubMed     Text format     Abstract available
    
    
    
59. SABRA MM, Sherman EJ, Tuttle RM
    Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30690.
    PubMed     Text format     Abstract available
    
    
    March 2017
60. ZHANG L, Jiang T, Li X, Wang Y, et al
    Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30677.
    PubMed     Text format     Abstract available
    
    
    
61. SUN B, Brooks ED, Komaki RU, Liao Z, et al
    7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30693.
    PubMed     Text format     Abstract available
    
    
    
62. KEAM B, Kim MK, Choi Y, Choi SJ, et al
    Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.
    Cancer. 2017;123:841-848.
    PubMed     Text format     Abstract available
    
    
    February 2017
63. VERMA V, Shostrom VK, Kumar SS, Zhen W, et al
    Multi-institutional experience of stereotactic body radiotherapy for large (>/=5 centimeters) non-small cell lung tumors.
    Cancer. 2017;123:688-696.
    PubMed     Text format     Abstract available
    
    
    
64. SAAB J, Hoda RS, Narula N, Hoda SA, et al
    Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens.
    Cancer. 2017;125:128-137.
    PubMed     Text format     Abstract available
    
    
    
65. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    PubMed     Text format     Abstract available
    
    
    January 2017
66. VELIZHEVA NP, Rechsteiner MP, Wong CE, Zhong Q, et al
    Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Cancer. 2017;125:30-40.
    PubMed     Text format     Abstract available
    
    
    December 2016
67. BISHOP JA, French CA, Ali SZ
    Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.
    Cancer. 2016;124:901-908.
    PubMed     Text format     Abstract available
    
    
    June 2016
68. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: